Use drugs sulfonylureas in the long term in patients with type II diabetes leads to reduced levels T. glucagon in the blood, This may contribute to lower blood sugar by these drugs. The mechanism of action of these drugs To reduce glucagon levels are not entirely clear, but may be due to an indirect effect by increasing the start of both insulin and somatostatin somatostatin And who in turn يثبطون secretion of a cell (A cells ) In the pancreas. In the absence of beta cells, as is the case for patients with type I diabetes, as well as updated in experimental animals have sugar using AlstrepettosasanStreptozacin , The sulfonylureas drugs in fact lead to a slight increase in the secretion of glucagon.
Labels
sulfonylureas